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Background: Tenofovirdisoproxilfumarate (TDF) is a nucleotide analogue widely recommended in international HIV
treatment guidelines. The association of TDF and renal dysfunction has remained an area of interest.
Findings: We conducted a retrospective review of all patients on TDF from July 2007 to December 2009 in our
institution and evaluated their renal function. Absolute change of creatinine clearance (CLCr) using Cockroft-Gault
equation from baseline was calculated at 6, 12, 18 and 24 months. Overall, 226 patients were included in the study.
Ninety percent were male. The median age was 46 yrs old (23–82), median weight was 60 kg (IQR 53.75-68),
median CD4 count was 127 cells/mm3 (IQR 38–258) and median CLCr 82.7 mL/min (IQR 71.4-101.7) on initiation of
TDF. The median decline of CLCr from baseline was −3.9 ml/min (IQR −12.3 to 7.6), and −3.6 ml/min (IQR −12.4 to
6.7) at 12 (n = 102), 24 months (n = 75) respectively. Eighteen of 226 patients had a decline in renal function to
</=50 ml/min. Majority of which had an improvement of CLCr on follow up. Only 80% of patients ever received
monitoring of renal function.
Conclusion: While we noted renal toxicity to be rare and transient among our cohort receiving TDF as part of their
ARV regimen, these results reflect the short term renal effects of TDF given that ARV treatment is lifelong. Given
that laboratory monitoring may be difficult to implement in many situations, future prospective studies looking into
an evidence based algorithm for less frequent renal function monitoring than current guideline recommendations
may be helpful.
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Tenofovirdisoproxilfumarate (TDF) is a nucleotide
analogue widely recommended in international HIV
treatment guidelines [1-3].
The association of TDF and renal dysfunction has
remained an area of interest. In several clinical trials,
TDF has been found to be safe with renal effects
reported to be 1-3% with minimal differences from com-
parative non TDF arms [4-7]. However, several case
reports and series show patients treated with TDF may
present with acute renal failure, Fanconi syndrome and
diabetes insipidus. These reports suggested that TDF
could cause renal tubular injury and decline in creatin-
ine clearance (CLCr) [8-14]. A meta-analysis of prospect-
ive studies comparing TDF-containing with non-TDF* Correspondence: Arlene_CHUA@ttsh.com.sg
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reproduction in any medium, provided the orcontaining ARV regimens showed that TDF use was
associated with statistically significant loss of renal func-
tion and the clinical effect was modest [15].
The mechanism by which TDF causes renal toxicity is
not well characterized and some studies suggest TDF
induces mitochondrial toxicity [16]. Pharmacogenetics
has been explored as one potential risk factor [17]. Goi-
coechea et al have reported treatment with TDF and a
protease inhibitor (PI) to be associated with greater
declines in renal function compared to TDF with non-
nucleoside reverse transcriptase inhibitor (NNRTI)
based therapy [18].
Current international guidelines [2] recommend moni-
toring renal function at ARV initiation or modification,
2–8 weeks post ARV initiation or modification and every
3–6 months thereafter and when clinically indicated.
Dose reduction for TDF is recommended when the falls
CLCr below 50 ml/min.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Characteristics of patients who received
Tenofovir, TTSH, Singapore, Jul. 2007 – Dec. 2009
(N= 226)










Median (range) 46 (23 – 82)
Weight
Median (IQR) 60.0 [53.75 - 68.0]
ART Regimen
NNRTI-based 118 (52.2)
PI - based 108 (47.8)
Co-morbidity
Hepatitis B co-infection 63 (27.9)
Diabetes mellitus 26 (11.5)
Hypertension 23 (10.2)
Chronic renal disease 2 (0.9)
CD4 cell count (cells/mm3)
Median [IQR] 127 [38–258]
Viral Load (Log10 Copies/mL)
Median [IQR] 4.9 [4.2-5.5]
Creatinine clearance (mL/min)
Median [IQR] 82.7 [71.4-101.7]
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function in our local cohort of HIV infected individuals
receiving TDF in Singapore as well as investigated the
changes of renal function over time. We specifically
looked at the proportion of patients whose CLCr fell
below 50 ml/min requiring TDF dose adjustment after
treatment and subsequent management of these cases.
Methods
We conducted a retrospective review of all patients who
were started on an antiretroviral regimen containing
TDF from July 2007 to December 2009 at the Commu-
nicable Disease Centre (CDC) at Tan Tock Seng Hos-
pital (TTSH) in Singapore. Data was collected from
review of medical records. Data on demographics, ARV,
comorbidities and TDF dose were collected. Creatinine
clearance (CLCr) was calculated using the Cockcroft-
Gault equation.
Absolute change of CLCr from baseline was calculated
for each patient at 3, 6, 9, 12, 15, 18, 21 and 24 months.
Not all patients had the same frequency of serum cre-
atinine monitoring because of physician differences in
clinical management. When available, the CLCr at follow
up was calculated using the serum creatinine level clos-
est to the period of evaluation (+/− 1 month). Evalua-
tions were made on the associations of other variables
with change in CLCr, including age, ethnicity, sex, dia-
betes, hypertension, hepatitis B coinfection, presence of
chronic renal disease, CD4 cell count and NNRTI or PI
based regimen.
Monitoring of serum creatinine, appropriateness of
dose of TDF based on CLCr, and deaths among those
who developed renal toxicity were evaluated.
We defined renal toxicity as a reduction of CLCr to
</= 50 ml/min. It is recommended that the dosing
interval of TDF be modified for patients with a CLCr
of <50. Bygrave et al published their experience with
TDF defining renal toxicity by a reduction of CLCr to
</= 50 ml/min [19].
For the baseline characteristics we used medians and
interquartile ranges (IQRs) for continuous variables
while counts and proportions were used for categorical
variables. The proportion of creatinine measurements
performed at baseline and follow up were calculated.
The proportion of patients who received an appropriate
TDF dose based on baseline CLCr was obtained. The
median change of CLCr from baseline was calculated at
3, 6, 9, 12, 15, 18, 21 and 24 months. SPSS for Windows
version 18.0 (SPSS Inc. Chicago, IL, USA) was used for
all statistical analysis. All tests were two tailed. In all
tests, a p value <0.05 was considered significant. We
compared proportions using Fisher’s exact test, means
using ANOVA test and medians using Kruskal Wallis
test.This study was reviewed and approved by the Singapore
National Health Care Group (NHG) Domain Specific
Ethics Review Board Committee.Results
From July 2007 to December 2009, there were a total of
226 patients who received an antiretroviral regimen con-
taining TDF. Baseline demographic and clinical charac-
teristics of patients receiving TDF are presented in
Table 1.
A total of 16 patients had discontinuation of TDF. The
reasons for stopping therapy included virological failure
(n = 11), change of TDF to another NRTI due to patient
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toxicity (n = 2).
There were 166 (73.5%) patients with a baseline cre-
atinine measured at initiation of TDF and the median
CLCr was 82.7 mL/min (IQR 71.4-101.7). Subsequent
serum creatinine was obtained in 192 (84.9%) patients
within 6 months and 202 (89.4%) within 12 months of
starting TDF. The patients did not have the same fre-
quency of serum creatinine measurements during the
follow up period. Creatinine has been checked for only
53% (102/194) and 77% (75/98) for patients in follow up
at 12 and 24 month respectively.
Of those patients who had a baseline serum creatinine
at initiation, 12 patients had a calculated CLCr of <50 mL/
min. Among these, 11/12 (92%) had an incorrect TDF
dose. The dose of TDF was adjusted for 5 patients on the
following visit, and for 3 patients, repeat CLCr was
>50 mL/min requiring no further TDF dose adjustment.
The median decline of CLCr from baseline of CLCr
was −3.9 ml/min (IQR −12.3 to 7.6) and −3.6 ml/
min (IQR −12.4 to 6.7) at 12 (n = 102) and 24 months
(n = 75) respectively (Figure 1). There was no statis-
tical association between the trend in CLCr and the
CD4 count,, age, NNRTI or PI based ARV regimen,
or the presence of an existing co-morbidity (Hepatitis
B coinfection, hypertension or diabetes).
There were 18 patients who had a baseline CLCr of
>50 mL/min who developed toxicity on follow up with
a subsequent CLCr of</= 50 mL/min. The onset of CLCr
decline to </=50 mL/min in 10/18 patients was within
6 months of TDF initiation. The CLCr decline was >25%
for 16 patients and >50% for 2 patients. Only 1 patient
developed severe renal impairment (CLCr <30 ml/min).Figure 1 Median Creatinine Clearance over time.There were 3/18 that died of which none were attributed
to TDF toxicity. Of the 15 remaining patients, 2 were
switched to a non TDF containing regimen and 13
patients remained on TDF despite renal impairment.
The CLCr improved without dose adjustment in the ma-
jority of these patients (10 of 13). The remaining 3/10
patients had TDF dose adjustment to 300 mg once every
other day based on reduced CLCr.
We compared these 18 patients with those who did
not have any renal toxicity and found no differences in
terms of their baseline CD4 count, age, gender, presence
of hypertension, diabetes, or hepatitis B status. There
were 12/18 patients who were on a PI based regimen.
There was a tendency for reduction of ClCr among those
who had a PI based regimen (p = 0.38, at 3 months)
however this was not significant.
Discussion
Our study showed that in an Asian HIV population, ma-
jority of whom had a low CD4 count but relatively nor-
mal CLCr, the proportion of patients who develop renal
toxicity is low (2.2%; 5/226). While use of protease in-
hibitor has been associated with greater decline in renal
function [18], we are unable to show any significant dif-
ference which may be attributed to the small number in
our study.
In our clinical practice setting around 80% of patients
on TDF ever received monitoring of renal function.
The data on TDF related renal toxicity in an Asian
HIV cohort is limited. A recent observational Japanese
cohort study showed that the incidence of renal dysfunc-
tion in low body weight patients treated with tenofovir
was twice as high compared to those treated with
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dictor of TDF associated renal toxicity in Thai patients
is currently ongoing [21].
One limitation of our study is that we calculated CLCr
using the Cockroft-Gault equation. Studies have shown
that the abbreviated MDRD equation performs better
than the Cockroft Gault equation for non Caucasian eth-
nic groups [22-24].
Other limitations of our study are that we did not have
a non TDF comparator group. Our follow up period is
limited to up to 24 months which only 98 out of 226
patients have achieved. It would be important to see
CLCr trend over longer periods as other studies have
shown decline in renal function long term [25,26].
Limitations of using retrospective data obtained from
medical records include incomplete data, difficulty in
verifying documented information, and variability in the
quality of documentation among physicians. Moreover,
not all patients had creatinine measured during the
designated follow up period due to physician variability
in clinical practice. Our study cohort includes both ARV
naïve and experienced patients which makes our results
difficult to compare with other studies.
Our study showed that renal toxicity was uncommon
and transient which confirms previous studies on TDF.
Given that ARV therapy is lifelong, the results of our
study reflect the short term renal effects of TDF. Current
international guidelines recommend monitoring renal
function at ARV initiation or modification, 2–8 weeks
and every 3–6 months thereafter [2]. Given that labora-
tory monitoring may be difficult to implement in many
situations, future prospective studies looking into an evi-
dence based algorithm for less frequent renal function
monitoring than current guideline recommendations may
be helpful.
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